| |
Decentralized clinical trials (DCTs) are redefining clinical research beyond the confines of traditional clinical trial sites. This recent shift presents immense promise for pediatric rare disease research – offering hope to patients and their families as they navigate the uncertainty of their diagnoses. Read our checklist to explore expert insights for the implementation of decentralized clinical trials in pediatric rare diseases. +(002)+120w.png)
|
|
Today’s Big NewsApr 18, 2024 |
| By Nick Paul Taylor The backing singer in AbbVie’s $8.7 billion takeover of Cerevel Therapeutics is having its moment in the spotlight. |
|
|
|
By Gabrielle Masson Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. |
By Annalee Armstrong A thinner, leaner biotech forest arrived at the American Association for Cancer Research conference in San Diego ready to showcase the budding data that has sprouted as a result of difficult decisions made during the sector’s so-called “nuclear winter.” |
By Gabrielle Masson Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA accepting a rolling new drug application for the company’s NaV1.8 inhibitor VX-548 in moderate-to-severe acute pain. |
|
Tuesday, April 23, 2024 | 2:00pm ET | 11:00am PT If you are embarking on the exciting journey of moving labs, this webinar is for you! Join us on April 23rd to learn from real-life stories the critical steps to a successful move and the common budget-draining mistakes to avoid. Register today! 
|
|
By Max Bayer Biopharma dealmaking continues to be one of the most encouraging signs of the industry's (partial) recovery. The number of deals in the first quarter more than doubled from the same period a year ago. |
By Helen Floersh Charles River Laboratories, a major supplier of animal models, has launched a new project to cut down on animal testing in drug discovery. |
By Zoey Becker The FDA now expects most doses of the drugs to be in "limited availability" through the second quarter. Just a few weeks ago, the agency projected the supply strain would ease ease in April. |
By Conor Hale 23andMe’s co-founder and CEO Anne Wojcicki has put in motion a plan to take the company private after the stock value of the DNA testing provider has collapsed by more than 97% since its multibillion-dollar market debut just three years ago. |
By Eric Sagonowsky AbbVie's Rinvoq has racked up seven FDA approvals in recent years, and another expansion into giant cell arteritis could be in the cards after a positive trial. |
By Conor Hale The company’s all-digital cell morphology analysis platform employs high-resolution microscopic imaging of samples taken during bone marrow aspiration procedures and automatically highlights different hematopoietic cell types in stained blood smears. |
By Paige Minemyer Elevance Health's first-quarter profit grew by double digits year over year, reaching $2.2 billion, according to its earnings report released Thursday morning. |
Fierce podcasts Don’t miss an episode |
| Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join usto learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
